Inclusion Criteria:

- ECOG performance status of 0-2.

- Histologically proven gastric or gastro-esophageal junction adenocarcinoma.

- At least unidimensional measurable disease. If a unique metastasis constitutes the
only disease sign, it requires histological confirmation.

- First line locally unresectable or metastatic gastric cancer.

- Relapsing gastric cancer after local and/or systemic treatment with a post-surgical
period of at least 4 weeks, a post-adjuvant or neoadjuvant chemoradiotherapy period
of at least 6 months.

- Serum bilirubin < 2 mg/dl

- Serum creatinine < or = 2 mg/dl

- Hemoglobin > or = 10 g/dl

- Absolute neutrophil count > or = 2000/dl

- Platelet count >or = 100, 000/dl

- AST/ALT < or = 2.5 time-fold the institutional normal upper limit

- Alkaline phosphatase < or = 5 time-fold the institutional normal upper limit

- Imagenological evaluation of the patient at least 2 weeks prior to the drug infusion

- Laboratory tests at least 1 week prior to the first infusion

- Patient available for follow up and able to answer to the quality of life
questionnaire

Exclusion Criteria:

- Symptomatic sensorial peripheral neuropathy

- Uncontrolled concomitant disease

- Another malignant neoplastic disease diagnosed within the previous 5 years to the
diagnosis of advanced or metastatic gastric cancer, with the exception of 'in situ'
cervix carcinoma or non-melanoma skin cancer

- Concomitant antitumoral treatment

- Cerebral metastases

- Unstable heart disease, even though in treatment

- Myocardial infarction within the last 6 months

- Radiotherapy within the last 6 weeks, surgery within the last 4 weeks, or
chemotherapy within the last 6 months.

- Pregnancy or nursing ( or women in reproductive life without adequate contraception)

- Significant neurological or psychiatric disorders.